Anika Therapeutics Diluted Loss Per Share for 1999 is $0.24 Versus $0.26 as Previously Reported.Business Editors WOBURN, Mass.--(BUSINESS WIRE)--March 31, 2000 Anika Therapeutics, Inc. (Nasdaq:ANIK ANIK Canadian COMSAT ) reported today that its net loss per diluted share for the year ended December 31, 1999 is $0.24 per share rather than $0.26 per share as previously reported. Income per diluted share before the cumulative effect of a change in accounting principle for the year ended December 31, 1999 is $0.11 per share rather than $0.12 per share as previously reported. The differences in reported per share amounts derive from the computation of diluted shares. There has been no change to either net income or income before cumulative effect of change in accounting principle. About Anika Therapeutics Anika Therapeutics, Inc. (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid hyaluronic acid: see mucopolysaccharide. Hyaluronic acid A polysaccharide which is an integral part of the gel-like substance of animal connective tissue; it supposedly serves as a lubricant and shock absorbent in the joints. (HA), a naturally occurring, biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. polymer found throughout the body. In addition to ORTHOVISC(R), a treatment for osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the knee (not approved for sale in the U.S.), Anika markets HYVISC(R) in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures AMVISC(R) and AMVISC(R)Plus, HA viscoelastic Adj. 1. viscoelastic - having viscous as well as elastic properties natural philosophy, physics - the science of matter and energy and their interactions; "his favorite subject was physics" products for ophthalmic surgery, for Bausch & Lomb Surgical. Therapies currently under development include INCERT(R), a family of HA formulations designed to prevent post-surgical adhesions. Anika is also collaborating with Orquest, Inc. to manufacture OSSIGEL(R), an injectable formulation of basic fibroblast growth factor Basic fibroblast growth factor, also known as bFGF or FGF2, is a member of the fibroblast growth factor family. In normal tissue, basic fibroblast growth factor is present in basement membranes and in the subendothelial extracellular matrix of blood combined with HA designed to accelerate the healing of bone fractures. (AMVISC(R) is a registered trademark of Bausch & Lomb, Incorporated and OSSIGEL(R) is a registered trademark of Orquest, Inc.) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion